Know if it’s recalled — and exactly what to do.

JEEP GRAND CHEROKEE (2024) recall — Electrical System

Rising Pharma Holding, Inc. recalls Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count (NDC 57237-018-30), b) 90 count (NDC 57237-018-90) and c)

Rising Pharma recalls Duloxetine Delayed-Release Capsules 30mg (NDC 57237-018-30) and 90mg (NDC 57237-018-90) due to presence of N-nitroso-duloxetine impurity above safety limits. This may pose health risks.

Rising Pharma Holding, Inc. recalls Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) 90 count NDC 57237-019-90 and c) 1000 count (NDC

Rising Pharma recalls Duloxetine DR Capsules 60mg (NDC 57237-019-30, 57237-019-90, 57237-019-99) due to presence of N-nitroso-duloxetine impurity above safety limits. Consumers should check product details and contact Rising Pharma for guidance.

Mylan Institutional, Inc. recalls Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets

Mylan recalls 137 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. Affected units have specific NDC and expiration dates. Contact Mylan for remedy.

Mylan Institutional, Inc. recalls Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets

Mylan recalls 100-mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or overmedication. No remedy specified in official notice.

Mylan Institutional, Inc. recalls Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets

Mylan recalls 175 mcg levothyroxine tablets due to potential subpotent or superpotent drug levels. This may cause ineffective treatment or adverse effects. Check NDC 42292-040-20 for affected lots.

KIA EV6 (2022) recall — Electrical System